Available Forms: Injection
Available Strengths: 100 mg/mL
Reference Brands: Leqembi (USA/EU)
Category: Neurology
Lecanemab-irmb is a humanized monoclonal antibody used for early Alzheimer’s disease. It targets and clears amyloid-beta protofibrils to help slow cognitive and functional decline. The treatment is administered under medical supervision as part of a disease-modifying therapy program for patients with mild cognitive impairment or mild dementia due to Alzheimer’s.
Quick Response Guaranteed | Verified Suppliers
Lecanemab-irmb is used for treating early Alzheimer’s disease, specifically in patients with mild cognitive impairment or mild dementia who have confirmed amyloid-beta buildup in the brain.
It is a humanized IgG1 monoclonal antibody developed to target aggregated forms of amyloid-beta (Aβ) in the brain.
The trade name is Leqembi.
It is developed and marketed by Eisai in partnership with Biogen.
The generic name is Lecanemab-irmb.
The brand name is Leqembi.
It is manufactured by Eisai facilities under global production and quality standards.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP